Send to:

Choose Destination
See comment in PubMed Commons below
CPT Pharmacometrics Syst Pharmacol. 2013 Sep 4;2:e71. doi: 10.1038/psp.2013.38.

Using network biology to bridge pharmacokinetics and pharmacodynamics in oncology.

Author information

  • 1Merrimack Pharmaceuticals Inc., Cambridge, Massachusetts, USA.


If mathematical modeling is to be used effectively in cancer drug development, future models must take into account both the mechanistic details of cellular signal transduction networks and the pharmacokinetics (PK) of drugs used to inhibit their oncogenic activity. In this perspective, we present an approach to building multiscale models that capture systems-level architectural features of oncogenic signaling networks, and describe how these models can be used to design combination therapies and identify predictive biomarkers in silico.CPT: Pharmacometrics & Systems Pharmacology (2013) 2, e71; doi:10.1038/psp.2013.38; published online 4 September 2013.

Free PMC Article
PubMed Commons home

PubMed Commons

How to join PubMed Commons

    Supplemental Content

    Full text links

    Icon for Wiley Icon for PubMed Central
    Loading ...
    Write to the Help Desk